NCT04831944 is a Phase 1 clinical trial of parsaclisib in Advanced Malignancies, sponsored by Incyte Corporation.

Who is sponsoring NCT04831944?

NCT04831944 is sponsored by Incyte Corporation.

What drugs are being tested in NCT04831944?

Interventions in NCT04831944: parsaclisib.

What condition does NCT04831944 study?

NCT04831944 studies Advanced Malignancies.

Is NCT04831944 still recruiting?

NCT04831944 is currently completed. Last updated 26 August 2022.

Last reviewed 2022-08-26 · How we verify

NCT04831944

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

Completed Phase 1 Last updated 26 August 2022

What this trial tests

Phase 1 trial testing parsaclisib in Advanced Malignancies in 21 participants. Completed in 11 March 2022.

Timeline

29 March 2021

Primary endpoint
10 March 2022

11 March 2022

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	21
Start date	29 March 2021
Primary completion	10 March 2022
Estimated completion	11 March 2022
Sites	5 locations across United States

Drugs / interventions tested

parsaclisib — full drug profile →

Conditions studied

Advanced Malignancies — all drugs for Advanced Malignancies →

Sponsor

Incyte Corporation — full company profile →

Who can join

Adults 18 to 80, any sex, with Advanced Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immunometabolism in cancer: basic mechanisms and new targeting strategy.
Su R, Shao Y, Huang M, Liu D, et al · · 2024 · cited 28× · PMID 38755125 · DOI 10.1038/s41420-024-02006-2

Verify or expand the search:

Other trials of parsaclisib

Trials testing the same drug.

NCT05867030 — Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma · Phase 1 · withdrawn
NCT04796922 — To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and · Phase 3 · withdrawn
NCT04849715 — A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnos · Phase 3 · withdrawn
NCT04809467 — A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non · Phase 1, PHASE2 · terminated
NCT04551053 — To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Re · Phase 3 · terminated

Other recruiting trials for Advanced Malignancies

Currently open trials in the same condition.

NCT06937957 — A Study of BR111 in Patients With Advanced Malignancies · Phase 1 · recruiting
NCT06401356 — An Extension Study for Patients Previously Enrolled in Studies With Pelabresib · Phase 3 · recruiting
NCT06468098 — A Study of IBI363 in Subjects With Advanced Malignancies · Phase 1 · recruiting
NCT06717880 — A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer · Phase 1 · recruiting
NCT05059522 — Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing · Phase 3 · active not recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04831944 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 26 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04831944.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing